AN2 Therapeutics Q2 net loss $15.8M; expects Phase 2 enrollment completion and Phase 3 start in Sep 2023

AN2 Therapeutics, Inc.

2023-Q2 EPS reported -$1.60

Net loss $15.8M for Q2 2023 vs $10.1M prior year; R&D expenses increased on clinical trial costs.
Cash, cash equivalents and investments $95.3M at June 30, 2023, after ATM offering of 2.5M shares at $8.00.
Phase 2 portion of pivotal epetraborole study for treatment-refractory MAC lung disease enrollment to finish in August; Phase 3 begins September.
Top-line Phase 2 data expected summer 2024; over 90 active clinical sites across U.S., Japan, South Korea, Australia.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

AN2 Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income Net loss was $15.8 million for the three months ended June 30, 2023.

Period: the quarter ended June 30, 2023
Net income: Net loss was $15.8 million for the three months ended June 30, 2023
Result: reported results

Exact text from the filing

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended June 30, 2023.

View on SEC.gov

21 earnings releases filed in the last 30 days. Browse all earnings releases →

AN2 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-041358

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.